IMP-7068 is under clinical development by IMPACT Therapeutics and currently in Phase I for Uterine Cancer. According to GlobalData, Phase I drugs for Uterine Cancer have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how IMP-7068’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
IMP-7068 overview
IMP-7068 is under development for the treatment of advanced solid tumors including colorectal cancer and uterine serous carcinoma. The drug candidate is new chemical entity acts by targeting wee1 tyrosine kinase and is being developed based on the DNA damage repair (DDR) drug discovery platform.
IMPACT Therapeutics overview
IMPACT Therapeutics (IMPACT) is a developer of therapeutics to treat cancer and other life-threatening diseases. The company provides products such as microtubule inhibitors, PARP-1 inhibitors, and Hedgehog pathway inhibitors for oncology. Its PARP-1 inhibitor is an oral bioavailability; and IMP04297 is an efficacious in several animal cancer models. The company also develops IMP3138, a small molecular microtubule inhibitor clinical candidate with advantages in vitro and in vivo over paclitaxel. It also operates oncology drug discovery and several anticancer drug development projects. IMPACT is headquartered in Nanjing, China.
For a complete picture of IMP-7068’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
Smarter leaders trust GlobalData
Premium Insights Likelihood of Approval and Phase Transition Success Rate Model - IMP-7068 in Uterine Cancer
Premium Insights
The gold standard of business intelligence.
